Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability

[1] Kanis JA(2014)The osteoporosis treatment gap J Bone Miner Res 29 1926-1928

[2] Svedbom A(2016)Osteoporosis therapy in postmenopausal women with high risk of fracture JAMA 316 715-716

[3] Harvey N(2016)Binding selectivity of abaloparatide for pth-type-1-receptor conformations and effects on downstream signaling Endocrinology 157 141-149

[4] McCloskey EV(2015)Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis J Clin Endocrinol Metab 100 697-706

[5] Cappola AR(2016)Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial JAMA 316 722-733

[6] Shoback DM(2008)Frax and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 385-397

[7] Hattersley G(2015)FRAX and the effect of teriparatide on vertebral and non-vertebral fracture Osteoporos Int 26 2677-2684

[8] Dean T(2012)Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with frax J Bone Miner Res 27 1480-1486

[9] Corbin BA(2017)The effect of abaloparatide-sc on fracture risk is independent of baseline frax fracture probability: a post hoc analysis of the ACTIVE study J Bone Miner Res 32 1625-1631

[10] Bahar H(2009)Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study Osteoporos Int 20 811-817

[1] Kanis JA(2014)The osteoporosis treatment gap J Bone Miner Res 29 1926-1928

[2] Svedbom A(2016)Osteoporosis therapy in postmenopausal women with high risk of fracture JAMA 316 715-716

[3] Harvey N(2016)Binding selectivity of abaloparatide for pth-type-1-receptor conformations and effects on downstream signaling Endocrinology 157 141-149

[4] McCloskey EV(2015)Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis J Clin Endocrinol Metab 100 697-706

[5] Cappola AR(2016)Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial JAMA 316 722-733

[6] Shoback DM(2008)Frax and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 385-397

[7] Hattersley G(2015)FRAX and the effect of teriparatide on vertebral and non-vertebral fracture Osteoporos Int 26 2677-2684

[8] Dean T(2012)Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with frax J Bone Miner Res 27 1480-1486

[9] Corbin BA(2017)The effect of abaloparatide-sc on fracture risk is independent of baseline frax fracture probability: a post hoc analysis of the ACTIVE study J Bone Miner Res 32 1625-1631

[10] Bahar H(2009)Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study Osteoporos Int 20 811-817